Author Correction: A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapy

Nat Biotechnol. 2020 Apr;38(4):503. doi: 10.1038/s41587-020-0461-z.

Greta Giordano-Attianese^#^{1

2}, Pablo Gainza^#^{3

4}, Elise Gray-Gaillard^#^{1

2}, Elisabetta Cribioli^{1

2}, Sailan Shui^{3

4}, Seonghoon Kim⁵, Mi-Jeong Kwak⁵, Sabrina Vollers^{3

4}, Angel De Jesus Corria Osorio^{1

2}, Patrick Reichenbach^{1

2}, Jaume Bonet^{3

4}, Byung-Ha Oh⁵, Melita Irving^{6

7}, George Coukos^{8

9}, Bruno E Correia^{10

11}

¹ Ludwig Institute for Cancer Research, University of Lausanne (UNIL), Epalinges, Switzerland.
² Department of Oncology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.
³ Institute of Bioengineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
⁴ Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland.
⁵ Department of Biological Sciences, Institute for the Biocentury, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Korea.
⁶ Ludwig Institute for Cancer Research, University of Lausanne (UNIL), Epalinges, Switzerland. melita.irving@unil.ch.
⁷ Department of Oncology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland. melita.irving@unil.ch.
⁸ Ludwig Institute for Cancer Research, University of Lausanne (UNIL), Epalinges, Switzerland. george.coukos@unil.ch.
⁹ Department of Oncology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland. george.coukos@unil.ch.
¹⁰ Institute of Bioengineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland. bruno.correia@epfl.ch.
¹¹ Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland. bruno.correia@epfl.ch.

^# Contributed equally.

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.